Why Lundbeck’s INFUSE study could broaden how migraine treatment success is measured
Lundbeck’s new Vyepti data highlight migraine-related cognitive symptom gains. Read what the INFUSE study could change for clinicians and the CGRP market.
What Grace Therapeutics’ STRIVE-ON data may change in neurocritical care
Grace Therapeutics’ GTx-104 heads to AAN 2026 just before FDA decision day. Find out what this could change in neurocritical care.